CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 364 enrolled
Drug / intervention
Teriparatide +1 moredrug
Likely dose
Teriparatide 20 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00414973
NCT00414973Phase 3Completed
CompareCT.gov

Comparison of Teriparatide and Calcitonin in the Treatment of Men and Postmenopausal Women With Osteoporosis

Eli Lilly and Company·interventional·Posted Dec 22, 2006·Updated Oct 28, 2009

In Brief

A Phase 3 clinical trial evaluating Teriparatide and Salmon Calcitonin for Osteoporosis. Completed, enrolled 364 participants across 5 sites.

Detailed Summary

The purpose of this study is to compare the effect of injectable teriparatide to intranasal salmon calcitonin on lumbar spine bone mineral density, in the treatment of Chinese patients with established osteoporosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 22, 2006
Enrollment StartDec 1, 2006
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.5 years ago

Interventions

Teriparatidedrug

Subcutaneous, 20 micrograms/day, 24 weeks

Salmon Calcitonindrug

Intranasal, 200 International Units (IU)/day, 24 weeks